A phase I clinical study of SBFM-PL4, a COVID-19 compound
Latest Information Update: 26 Mar 2021
At a glance
- Drugs SBFM-PL4 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 26 Mar 2021 New trial record
- 23 Mar 2021 According to a Sunshine Biopharma media release, the company plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting.